Views & Analysis Three NICE thresholds for cost-effectiveness: does that make... NICE wants a new, third threshold for rare disease drugs - but what's the evidence behind it?
Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
News Price cut brings ‘breakthrough’ NICE approval of Perjeta NICE says price cut made approval possible, despite continuing uncertainty about benefits
News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News UK spurs prescribing of obesity jab Mounjaro with GP bonus Doctors in the UK will be given thousands of pounds in bonus payments from April for prescribing Eli Lilly's weight-loss drug Mounjaro.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
